8-K: Pulse Biosciences Announces $60 Million At-the-Market Equity Offering and Provides Preliminary Q2 2024 Financial Results

Pulse Biosciences has entered into an agreement to sell up to $60 million of its common stock through an at-the-market offering and has released preliminary unaudited financial results for the second quarter of 2024.

Summary

• Pulse Biosciences has entered into an equity distribution agreement with Canaccord Genuity LLC and Needham & Company, LLC to sell up to $60 million of its common stock.
• The company is not obligated to sell any shares and may suspend sales at any time.
• The sales agents will use commercially reasonable efforts to sell shares at market prices or negotiated prices, and will receive a commission of up to 3.0% of the gross sales price.
• Pulse Biosciences has also released preliminary, unaudited financial results for the three months ended June 30, 2024.
• The company estimates cash and cash equivalents between $26.0 million and $26.5 million, excluding $60 million from a rights offering in July 2024.
• GAAP costs and expenses are estimated to be between $11.0 million and $13.0 million, with a GAAP net loss between $10.7 million and $12.7 million.
• Non-GAAP costs and expenses are estimated between $9.0 million and $10.0 million, with a non-GAAP net loss between $8.7 million and $9.7 million.
• These preliminary results are subject to final review and may differ from actual results.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. The capital raise is positive for funding, but the significant net loss and potential dilution are negative. The overall sentiment is cautiously negative.

Positives

• The equity distribution agreement provides Pulse Biosciences with a flexible way to raise capital.
• The company has access to $60 million in cash from a rights offering in July 2024, which is not included in the Q2 cash balance.
• The company is actively managing its expenses, as shown by the non-GAAP figures.

Negatives

• The company is reporting a significant net loss for the second quarter of 2024.
• The preliminary financial results are unaudited and subject to change.
• The company is relying on at-the-market offerings, which can be dilutive to existing shareholders.

Risks

• The company's final financial results may differ from the preliminary estimates.
• The company may not be able to sell all of the $60 million in shares under the distribution agreement.
• The at-the-market offering could dilute existing shareholders.
• The company's ongoing losses could raise concerns about its long-term financial viability.

Future Outlook

The company does not undertake any obligation to update any forward-looking statements, including financial projections or guidance.

Industry Context

At-the-market offerings are a common method for biotech companies to raise capital, especially when they are in the development stage and not yet generating significant revenue. The preliminary financial results are typical for a company in this stage of development.

Comparison to Industry Standards

• Many development-stage biotech companies utilize at-the-market offerings to raise capital, similar to Pulse Biosciences.
• Comparable companies in the medical device sector often report net losses during the development and clinical trial phases.
• The level of cash burn and the need for additional capital are typical for companies in this industry.

Stakeholder Impact

• Shareholders may experience dilution due to the at-the-market offering.
• Employees may be impacted by the company's financial performance.
• Customers and suppliers may be affected by the company's ability to continue operations.

Next Steps

• The company may sell shares of common stock through the sales agents.
• The company will complete its closing procedures for the fiscal quarter ended June 30, 2024.
• The company will file its full interim unaudited financial statements prepared in accordance with U.S. GAAP.

Key Dates

Keywords

equity offering, at-the-market, common stock, financial results, preliminary, GAAP, non-GAAP, net loss, cash equivalents, Pulse Biosciences